Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aromatase inhibitors as adjuvant therapy for breast cancer.
Montemurro F, Aglietta M, Del Mastro L. Montemurro F, et al. J Clin Oncol. 2009 May 20;27(15):2566-7. doi: 10.1200/JCO.2009.22.2695. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332706 No abstract available.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Del Mastro L, et al. Among authors: montemurro f. Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2. Lancet. 2015. PMID: 25740286 Clinical Trial.
Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Lambertini M, et al. Among authors: montemurro f. Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099741 Free PMC article.
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
Gori S, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, Bisagni G, Foglietta J, Santini D, Pavese I, Pellegrino A, Zambelli A, Vici P, Leonardi V, Barni S, Saracchini S, Bogina G, Marchetti F, Duranti S, Lunardi G, Montemurro F. Gori S, et al. Among authors: montemurro f. PLoS One. 2016 May 25;11(5):e0156221. doi: 10.1371/journal.pone.0156221. eCollection 2016. PLoS One. 2016. PMID: 27224517 Free PMC article.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups. Lambertini M, et al. Among authors: montemurro f. Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10. Eur J Cancer. 2017. PMID: 27951450 Clinical Trial.
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. Lambertini M, et al. Among authors: montemurro f. Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28479052
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: montemurro f. Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28969087 Free PMC article.
256 results